Inclusion Criteria:

- Patients with locally advanced or metastatic gastric adenocarcinoma, including
adenocarcinoma of the gastroesophageal junction who have progressed on a
fluoropyrimidine or taxane-containing regimen in any combination in one prior first
line treatment.

- EGOC performance status of 0,1 or 2

- Men and women, 18 years of age and older

Exclusion Criteria:

- Patients having received more than one previous systemic chemotherapy regimen in any
setting.

- Major abdominal surgery within 2 months or any other surgery under general anesthesia
within 4 weeks

- Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic
intestinal disease (e.g. ulcerative colitis)

- Prior radiation to >=30% of the bone marrow and/or radiation within 4 weeks prior to
enrollment

- Acute or chronic hepatitis

- Known HIV infection

- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
QTc interval >450 ms

- A history of additional risk factors for Torsade de Pointes (e.g., heart failure
hypokalemia, family history of Long QT Syndrome)